By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Diagnostics development firm Nuclea Biotechnologies has closed on a $4.7 million Series B financing round, its President and CEO confirmed to GenomeWeb Daily News.

Patrick Muraca said that the funds will be used for submission of its serum-based fatty acid synthase diagnostic test for prostate cancer to the US Food and Drug Administration for 510(k) clearance. Nuclea anticipates it will submit its application by the end of September, he said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.